Meeting
2014 ASCO Annual Meeting
Biomarker panel (TheraPrint) analyzed as a predictor of response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
Authors
Peter D. Beitsch
Dallas Surgical Group, Dallas, TX
Peter D. Beitsch , Lisette Stork , Femke De Snoo , Justine Peeters , Pat W. Whitworth
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Cytotoxic Chemotherapy
Clinical Trial Registration Number
NCT014799101
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 1026)
DOI
10.1200/jco.2014.32.15_suppl.1026
Abstract #
1026
Poster Bd #
19
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Transcriptional expression of Bcl-2 as predictive of response to neoadjuvant chemotherapy with trastuzumab in HER2-positive ER-positive breast cancer patients.
First Author: Maki Tanioka
Poster
2023 ASCO Annual Meeting
The proliferation biomarker SPAG5 expression in HER2 low and HER2 overexpression early breast cancer (BC) predicting tumour response to neoadjuvant chemotherapy (NACT) with and without trastuzumab.
First Author: Tarek Mohamed Ahmed Abdel-Fatah
Poster
2022 ASCO Annual Meeting
Molecular alterations associated with rapid progression following CDK4/6 inhibitors (CDKi) in metastatic hormone receptor–positive breast cancer (mHRBC).
First Author: Malinda T West
Poster
2019 ASCO Annual Meeting
In-depth gene expression analysis of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib-containing therapy in the Phase III MONALEESA-7 trial.
First Author: Yen-Shen Lu